Adgorif 40 Tablet 28's

Adgorif 40 Tablet 28's is an anti-cancer medicine used in the treatment of colorectal carcinoma. Colorectal cancer is a disease in which the cancer or the malignant cells grow out of control in the colon or rectum.

Adgorif 40 Tablet 28's contains Regorafenib as an active ingredient, which belongs to the class of medicines known as kinase inhibitors. It works by inhibiting the action of an enzyme (tyrosine kinase) and thus stops the abnormal growth of cancer cells.

Adgorif 40 Tablet 28's may cause certain side effects such as diarrhea, rash, tiredness, decreased appetite, nausea, weight loss, fatigue, stomach pain, loss of appetite, hoarseness, and dizziness. These side effects do not require medical attention and gradually resolve over time. Adgorif 40 Tablet 28's should be taken as advised by your doctor.

Avoid taking Adgorif 40 Tablet 28's if you are allergic to it or any other components of it. Before taking this medicine, inform your doctor if you have/had liver or kidney disease, gastrointestinal disorders, hypertension, heart problems, blood disorders, plan of any surgery, or any skin disorders. This medicine is not recommended for use in pregnant and breastfeeding mothers due to embryo-fetal toxicity.

Adgorif 40 Tablet 28's is used in the treatment of Colorectal Cancer. The detailed uses of Adgorif 40 Tablet 28's are as follows:

• Colorectal cancer: Adgorif 40 Tablet 28's is used for patients with metastatic colorectal cancer who have already received standard chemotherapy.
• Liver cancer (Hepatocellular carcinoma): Adgorif 40 Tablet 28's is used when the disease has progressed after sorafenib treatment.
• Gastrointestinal stromal tumors (GIST): Adgorif 40 Tablet 28's especially used when imatinib and sunitinib are no longer effective.

• Take Adgorif 40 Tablet 28's after a low-fat meal for best results.
• Adgorif 40 Tablet 28's should be taken once daily for the first 21 days of each 28-day cycle or as advised by your doctor.
• Swallow the medicine as a whole with a glass of water.
• Do not break, chew or crush Adgorif 40 Tablet 28's.

Adgorif 40 Tablet 28's contains, Regorafenib which used in the treatment of colorectal cancer (CRC) in patients who have previously been treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. It works by stopping the action of a tyrosine kinase enzyme that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body. In this way, Adgorif 40 Tablet 28's stops the body's production, spread and growth of cancerous cells.

To treat your condition effectually, continue taking Adgorif 40 Tablet 28's for the period that your doctor has prescribed. Avoid taking Adgorif 40 Tablet 28's if you are allergic to it or any other components present in it. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 18 years of age as the safety and efficacy are not established. Adgorif 40 Tablet 28's may cause hypertension, heart attack, hand-foot skin reaction, gastrointestinal perforation, haemorrhage, hepatotoxicity, and Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in some patients. Hence, inform your doctor about your complete medication and medical history before taking Adgorif 40 Tablet 28's. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Avoid driving and operating machines, as this medicine may cause dizziness.